###### Strengths and limitations of this study

-   It consisted of nationwide patients with type 2 diabetes.

-   It was based on a large sample of 459 726 patients with type 2 diabetes.

-   We conducted a propensity score matching with a ratio of 1:1 between pay-for-performance (P4P) participants and their counterparts not in the programme.

-   There have been very few studies investigating P4P effects on the reduction of stroke risk for diabetes.

-   The databases we employed did not include information about personal lifestyle and health behaviours.

Introduction {#s1}
============

In 2017, approximately 425 million people worldwide between 20 and 79 years of age were diabetic, and this figure is expected to increase to 629 million by 2045.[@R1] Type 2 diabetes accounts for more than 90% of the present cases globally.[@R2] The longer the duration of this disease, the more likely that macrovascular (atherosclerotic changes) and small vessel disorders (retinopathy, nephropathy and neuropathy) will develop, leading to blindness, kidney failure and amputation, while also contributing to death by heart attack and severe stroke.[@R2] Compared with non-diabetic patients, diabetes mellitus (DM) is an independent factor that causes the risk of a stroke to at least double.[@R3] Fortunately, it is possible to prevent or delay the occurrence of diabetic complications through intensive treatment and care. A 9-year follow-up study revealed that type 2 diabetes, when under intensive blood pressure control, reduced the composite of cardiovascular death, non-fatal myocardial infarction and non-fatal stroke by 25%.[@R4] A reduction in glycosylated haemoglobin (HbA1c) and systolic blood pressure below guideline target levels was associated with a lower risk of stroke.[@R5] More generally, risk factors for stroke are divided into those that are modifiable and non-modifiable. The former include hypertension, DM, cardiac causes, waist-to-hip ratio, current smoking, dyslipidaemia, alcohol consumption, physical inactivity, diet, and other.[@R6] The non-modifiable risk factors include age, sex, ethnicity and genetics.[@R6]

The Taiwanese healthcare system is a government-administered single-payer health insurance programme.[@R7] Its characteristics include comprehensive coverage, high accessibility, quick service and relatively low expenditure.[@R7] Taiwan's National Health Insurance (NHI) launched the pay-for-performance (P4P) programme in November 2001 to incentivise healthcare institutions to actively participate and to establish quality control indicators, including new patient acceptance rates, complete patient follow-up, poor control of HbA1c, good control of HbA1c and poor control of low-density lipoprotein (LDL).[@R8] A P4P arrangement is a management strategy that encourages healthcare providers to deliver high-quality care services and a high continuity of care.[@R9] In the P4P programme, physicians, nurses, pharmacists, nutritionists and case managers were required to form teams and co-care for patients with diabetes, using clearly established clinical guidelines,[@R10] which were largely based on the clinical practice guidelines of the American Diabetes Association.[@R11] In 2009, 27.56% of Taiwan's patients with diabetes had been voluntarily enrolled into the P4P programme by certified diabetes physicians or endocrinologists.[@R8] Patients in the P4P programme are followed by the same doctor who enrolled them. Patients who do not participate in the P4P received conventional treatment by physicians, who may or may not be certified diabetes specialists or endocrinologists.[@R12]

Beyond general care, participants in the DM P4P programme receive additional comprehensive services, including the taking of a full history, a physical examination, laboratory checks, the development of a management plan and diabetes self-management education. For this programme, there is a bonus examination payment to physicians and also a case management payment, both of which are paid by the NHI.[@R8] For Taiwan's Diabetes P4P programme, the amount of bonus payment is calculated using a point system, where the case management fee includes 400 points for the initial visit of any patient, 200 points for each follow-up visit (every 3 months) and 800 points for performing an annual assessment.[@R8] In this context, we note that 1 point is worth about 1 New Taiwan dollar (NT\$), and in 2019, US\$1 was worth NT\$31. To encourage physicians to improve the quality of medical care they provide, Taiwan's NHI offers financial incentives for higher levels of performance in the Diabetes P4P programme, based on four quality indicators, which are the rate of complete follow-ups, the positive HbA1c control rate (HbA1c \<7.0%), the negative HbA1 control rate (HbA1c \>9.5%) and the negative LDL rate (LDL \>130 mg/dL).[@R13] On the basis of these performance indicators, the extra payment for being in the top 25th percentile in quality metrics was combined for all four quality metrics (ie, the maximum extra points per patient is 1000).[@R13] Hospitals in the Taiwan healthcare industry are a closed system, and the incentive payments were given directly to healthcare organisations rather than to physicians. The distribution of bonuses to physicians in the P4P programme is based on the policy of each healthcare organisation.

A literature review of P4P programmes regarding patients with diabetes revealed that most focused on the quality of care, medical use and complication improvements.[@R12] One aspect of several earlier studies addressing this area has explored the association between P4P programmes and macrovascular complications (cardiovascular disease (CVD), stroke and peripheral vascular disease (PVD)) in patients with diabetes, but their research methods did not clarify whether the patients were hospitalised.[@R11] We think that patients suffering from the consequences of stroke should be hospitalised for treatment.

To date, very few studies have addressed the effect of P4P programmes on stroke risk in patients with type 2 diabetes, and none have explored the relationship between P4P programmes and risks by subtype of stroke (ischaemic and haemorrhagic) in patients with diabetes. Therefore, we used a national database to explore whether the P4P programme had positive effects on reducing the incidence of stroke (including ischaemic stroke and haemorrhagic stroke) in patients with diabetes and to determine the factors associated with incidence of stroke in patients with type 2 diabetes.

Methods {#s2}
=======

Data sources and participants {#s2-1}
-----------------------------

This was a retrospective cohort study, in which we collected nationwide data on patients with type 2 diabetes who were enrolled in the P4P programme and others who were not, during the period 2002--2012, and we followed them until the end of 2013 to investigate the risk of stroke between these two groups. We obtained the secondary data from Taiwan's NHI Research Database. The study participants were ≥45 years old and were newly diagnosed with type 2 DM, defined as having a primary diagnosis or subdiagnosis of DM (International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) 250, A code: A181) in one hospitalisation or ≥3 outpatient visits within 365 days. We excluded patients who were not newly diagnosed with type 2 diabetes based on the 2 years, 2000 and 2001, as washout period. Those with neonatal or gestational diabetes, glucose intolerance and type 1 diabetes as per the relevant ICD-9-CM codes[@R18] were excluded. The definition of P4P programme enrolment was based on the treatment code 'E4' for patients with DM being specified in medical records after they had been diagnosed with diabetes (n=229 863). An E4 was coded for any patient with diabetes being enrolled in the Diabetes P4P programme by Taiwan's NHI Administration. Patients with diabetes and a history of stroke were excluded. We estimated the propensity score of each patient with type 2 diabetes for inclusion in the P4P programme to perform a propensity score matching (PSM) aimed at reducing the possible selection bias of patients with and without P4P enrolment. A total of 459 726 participants were matched in a 1:1 ratio between patients with diabetes who participated in the P4P programme and those with diabetes who did not participate in it.

Patient and public involvement {#s2-2}
------------------------------

No patients were actively involved in this study, as it was based on the NHI Research Database, published by the Ministry of Health and Welfare, Taiwan.

Variable descriptions {#s2-3}
---------------------

The dependent variable was the occurrence of stroke in patients with type 2 diabetes. The key independent variable was whether or not the patients were enrolled in the P4P programme. Other control variables included characteristics of the patients (gender and age), their economic status (monthly salary, divided into six levels), environmental factors (residential area: level 1, highest degree of urbanisation; level 7, lowest degree of urbanisation[@R20]), health status (severity of Charlson Comorbidity Index (CCI) based on 17 comorbidity categories and severity of diabetic complications), characteristics of their primary medical institute (type of healthcare organisation: medical centre, regional hospital, district hospital, or clinic; ownership of organisation: public or private) and the characteristics of the primary treating physicians (an endocrinologist or not; the annual proportion of patients with diabetes of the primary physician: low, ≤25%; medium, 25%--75%; high, ≥75%). In addition, since Taiwan's NHI Program provides a free adult health check once every 3 years for people ≥40 years of age and once every year for those ≥65,[@R21] we used as a relevant variable whether patients had an adult health check before matching. Also, the duration of diabetes was divided into four levels (\<3, 3--6, 6--9 and ≥9 years).

We defined a stroke as the first primary diagnosis of stroke (ICD-9-CM 430.XX--438.XX) at admission during the study period. Haemorrhagic stroke and ischaemic stroke were defined as the leading causes of hospitalisation for stroke (ICD-9-CM 430.XX--432.XX and ICD-9-CM 433.XX--435.XX, respectively) during the study period. A patient's CCI was based on the relevant primary and secondary ICD-9-CM diagnostic codes in the previous 1-year medical record, which included hospitalisations, as well as emergency department and outpatient visits, which were all converted into a weighted numerical score according to comorbidity severity. The weighted scores were summed to calculate the CCI,[@R22] which we then scored as 0, 1 or ≥2 for this study. The Diabetes Complications Severity Index (DCSI) scores were classified as stroke, peripheral neuropathy, retinopathy, endocrine complications, nephropathy, PVD and CVD, according to the research of Young *et al*,[@R23] and then converted into weighted numerical scores (0, 1 or ≥2) based on the patient's ICD-9-CM primary and secondary diagnostic codes. The numerical scores were then summed to calculate the severity of diabetic complications.[@R23] The 'primary medical institution' was defined as the one most frequented by the patient for diabetes treatment. The institution with the most recent treatment date was named the primary medical institution in cases having the same number of visits to different medical institutions. The physician with the highest number of visits was defined as the primary care provider.

Main outcome measurements {#s2-4}
-------------------------

The primary outcome metric was the relative incidence risk of stroke between patients with type 2 diabetes who were enrolled in the P4P programme compared with those who were not. We likewise examined the risk of haemorrhagic stroke and the risk of ischaemic stroke in patients enrolled in the P4P programme compared with those who were not enrolled.

Statistical analysis {#s2-5}
--------------------

This study used SAS V.9.4 statistical software (SAS Institute) for descriptive and inferential statistics. To reduce the selection bias of patients with and without P4P enrolment, their characteristics, economic status, environmental factors, health status, nature of the primary medical institution, type of primary physician, use of an adult health check and the duration of diabetes were paired using PSM at a 1:1 ratio.

First, descriptive statistics analysed the characteristics of the patients and their P4P programme participation. The differences were presented as an average and as a percentage. Then, the log-rank test was used for inferential statistical analysis to determine whether there was a significant difference (p\<0.05) in the incidence of stroke between patients with type 2 diabetes who were enrolled in the P4P programme compared with those who were not and control variables. Finally, Cox proportional hazards model explored the relative risk of stroke in patients with type 2 diabetes enrolled in the P4P programme, compared with those not enrolled.

The incidence of stroke was viewed as an 'event', and others were marked as 'censored' in the analyses. We further conducted a stratification analysis to examine the effect of P4P enrolment on the risk of stroke for related variables in patients with type 2 diabetes.

Results {#s3}
=======

Descriptive statistics of patients with type 2 diabetes enrolled or not enrolled in the P4P programme {#s3-1}
-----------------------------------------------------------------------------------------------------

Following PSM, there were no significant statistical differences observed between the two groups (enrolled vs not enrolled in the P4P programme) ([table 1](#T1){ref-type="table"}). After matching, the study population consisted of 459 726 patients with newly diagnosed type 2 diabetes from 2002 to 2013 (50.01% female and 49.99% male). The largest patient group was those 55--64 years old (34.87%), with the numbers then decreasing with age. A monthly salary between US\$557 and US\$712 (in 2019, NT\$31=US\$1) was the most commonly earned by the participants (44.46%). A CCI=0 and a DCSI=0 were observed in most patients (63.16% and 79.21%, respectively). Regional hospitals were the most frequently visited (33.56%), and 76.56% of the visited medical institutions were privately owned. Non-endocrinologists accounted for 83.11% of the physicians visited by patients in this study. Most of the participants had diabetes for \<3 years (55.28%).

###### 

Comparisons of study participants after propensity score matching for P4P participating status

                                             1:1 matched                                                
  ------------------------------------------ ------------- -------- --------- ------- --------- ------- -------
  Total                                      459 726       100.00   229 863   50.00   229 863   50.00   
  Gender                                                                                                0.953
   Female                                    229 913       50.01    114 967   50.02   114 946   50.01   
   Male                                      229 813       49.99    114 896   49.98   114 917   49.99   
  Age                                                                                                   0.997
   45--54                                    139 411       30.32    69 704    30.32   69 707    30.33   
   55--64                                    160 294       34.87    80 165    34.88   80 129    34.86   
   65--74                                    108 797       23.67    54 369    23.65   54 428    23.68   
   ≥75                                       51 224        11.14    25 625    11.15   25 599    11.14   
  Monthly salary (US\$)                                                       0.435                     
   ≤557                                      24 032        5.23     12 033    5.23    11 999    5.22    
   557--735                                  204 412       44.46    102 053   44.40   102 359   44.53   
   735--929                                  107 915       23.47    53 887    23.44   54 028    23.50   
   929--1171                                 40 241        8.75     20 135    8.76    20 106    8.75    
   1171--1477                                42 068        9.15     21 242    9.24    20 826    9.06    
   ≥1477                                     41 058        8.93     20 513    8.92    20 545    8.94    
  CCI score                                                                                             
   0                                         290 375       63.16    145 165   63.15   145 210   63.17   0.991
   1                                         106 462       23.16    53 245    23.16   53 217    23.15   
   ≥2                                        62 889        13.68    31 453    13.68   31 436    13.68   
  DCSI score                                                                                    0.984   
   0                                         364 132       79.21    182 050   79.20   182 082   79.21   
   1                                         60 442        13.15    30 221    13.15   30 221    13.15   
   ≥2                                        35 152        7.65     17 592    7.65    17 560    7.64    
  Level of the healthcare organisation                     0.984                                        
   Medical centre                            82 286        17.90    41 188    17.92   41 098    17.88   
   Regional                                  154 294       33.56    77 158    33.57   77 136    33.56   
   District                                  93 194        20.27    46 579    20.26   46 615    20.28   
   Clinic                                    129 952       28.27    64 938    28.25   65 014    28.28   
  Ownership of organisation                                                   0.227                     
   Public                                    107 746       23.44    53 699    23.36   54 047    23.51   
   Non-public                                351 980       76.56    176 164   76.64   175 816   76.49   
  The main physician is an endocrinologist                 0.872                                        
   No                                        382 096       83.11    191 027   83.10   191 069   83.12   
   Yes                                       77 630        16.89    38 836    16.90   38 794    16.88   
  Duration of DM (years)                                                                        0.996   
   \<3                                       254 127       55.28    127 034   55.27   127 093   55.29   
   3--6                                      119 380       25.97    59 718    25.98   59 662    25.96   
   6--9                                      61 596        13.40    30 810    13.40   30 786    13.39   
   ≥9                                        24 623        5.36     12 301    5.35    12 322    5.36    

\*χ^2^ test.

CCI, Charlson Comorbidity Index; DCSI, Diabetes Complications Severity Index; DM, diabetes mellitus; P4P, pay for performance.

The effect of the P4P programme on incidence risk of stroke and relevant factors in patients with type 2 diabetes {#s3-2}
-----------------------------------------------------------------------------------------------------------------

The percentage of stroke incidence in patients with diabetes enrolled in the P4P programme was 6.41%, whereas for those not enrolled, it was 6.39%. A Cox proportional hazards model analysis found, after controlling for other variables, that the risk of stroke in patients enrolled in the P4P programme was 0.97 times that of the not enrolled patients (95% CI 0.95 to 0.99) ([table 2](#T2){ref-type="table"} and [figure 1](#F1){ref-type="fig"}). That is, the incidence of stroke in patients with diabetes enrolled in the P4P programme was less than that of the non-P4P group by 3%.

###### 

Relative risks of stroke and related factors in patients with type 2 diabetes

                                             No stroke   Stroke   P value\*   Adjusted model†                                   
  ------------------------------------------ ----------- -------- ----------- ----------------- --------- ------ -------------- ---------
  Total                                      430 308     93.60    29 418      6.40                                              
  P4P participating status                                                    0.057                                             
   Non-P4P                                   215 169     93.61    14 694      6.39                                              
   P4P                                       215 139     93.59    14 724      6.41                        0.97   0.95 to 0.99   0.022
  Gender                                                                                        \<0.001                         
   Female                                    216 760     94.28    13 153      5.72                                              
   Male                                      213 548     92.92    16 265      7.08                        1.42   1.39 to 1.45   \<0.001
  Patient's age (years)                                                       \<0.001                                           
   45--54                                    134 266     96.31    5145        3.69                                              
   55--64                                    151 675     94.62    8619        5.38                        1.52   1.47 to 1.57   \<0.001
   65--74                                    98 986      90.98    9811        9.02                        2.42   2.34 to 2.51   \<0.001
   ≥75                                       45 381      88.59    5843        11.41                       3.52   3.38 to 3.66   \<0.001
  Monthly salary (US\$)                                                       \<0.001                                           
   ≤557                                      22 435      93.35    1597        6.65                                              
   557--735                                  189 078     92.50    15 334      7.50                        0.99   0.94 to 1.04   0.584
   735--929                                  101 042     93.63    6873        6.37                        0.89   0.84 to 0.94   \<0.001
   929--1171                                 38 473      95.61    1768        4.39                        0.82   0.77 to 0.88   \<0.001
   1171--1477                                40 086      95.29    1982        4.71                        0.78   0.73 to 0.83   \<0.001
   ≥1477                                     39 194      95.46    1864        4.54                        0.68   0.64 to 0.73   \<0.001
  Urbanisation of residence area                                  \<0.001                                                       
   Level 1                                   118 433     94.70    6623        5.30                                              
   Level 2                                   134 561     94.07    8478        5.93                        1.08   1.05 to 1.12   \<0.001
   Level 3                                   64 792      93.33    4630        6.67                        1.14   1.1 to 1.19    \<0.001
   Level 4                                   65 460      92.32    5448        7.68                        1.21   1.17 to 1.26   \<0.001
   Level 5                                   10 661      91.98    929         8.02                        1.15   1.07 to 1.23   \<0.001
   Level 6                                   19 275      91.07    1890        8.93                        1.34   1.27 to 1.41   \<0.001
   Level 7                                   17 126      92.34    1420        7.66                        1.17   1.1 to 1.24    \<0.001
  CCI score                                                                   \<0.001                                           
   0                                         273 814     94.30    16 561      5.70                                              
   1                                         98 841      92.84    7621        7.16                        1.04   1.01 to 1.07   0.013
   ≥2                                        57 653      91.67    5236        8.33                        1.07   1.04 to 1.11   \<0.001
  DCSI score                                                      \<0.001                                                       
   0                                         342 788     94.14    21 344      5.86                                              
   1                                         55 999      92.65    4443        7.35                        1.09   1.06 to 1.13   \<0.001
   ≥2                                        31 521      89.67    3631        10.33                       1.41   1.36 to 1.46   \<0.001
  Level of the healthcare organisation                                        \<0.001                                           
   Medical centre                            77 925      94.70    4361        5.30                        0.9    0.86 to 0.93   \<0.001
   Regional                                  144 496     93.65    9798        6.35                        1.05   1.02 to 1.08   0.002
   District                                  86 243      92.54    6951        7.46                        1.08   1.05 to 1.12   \<0.001
   Clinic                                    121 644     93.61    8308        6.39                                              
  Ownership of organisation                                                   0.141                                             
   Public                                    100 928     93.67    6818        6.33                                              
   Non-public                                329 380     93.58    22 600      6.42                        1.11   1.08 to 1.14   \<0.001
  The main physician is an endocrinologist                        \<0.001                                                       
   No                                        356 581     93.32    25 515      6.68                                              
   Yes                                       73 727      94.97    3903        5.03                        0.91   0.87 to 0.94   \<0.001
  Physician's annual service volume                                           \<0.001                                           
   Low                                       6328        93.09    470         6.91                                              
   Medium                                    46 021      93.08    3424        6.92                        1.10   1.00 to 1.21   0.058
   High                                      377 959     93.67    25 524      6.33                        1.03   0.94 to 1.13   0.544
  Use of adult health check                                                   \<0.001                                           
   No                                        191 154     94.68    10 735      5.32                                              
   Yes                                       239 154     92.75    18 683      7.25                        0.92   0.89 to 0.94   \<0.001
  Duration of DM (years)                                                      \<0.001                                           
   \<3                                       239 792     94.36    14 335      5.64                                              
   3--6                                      109 852     92.02    9528        7.98                        1.20   1.17 to 1.23   \<0.001
   6--9                                      57 133      92.75    4463        7.25                        1.24   1.20 to 1.29   \<0.001
   ≥9                                        23 531      95.57    1092        4.43                        1.11   1.04 to 1.18   0.001

\*Log-rank test.

†Cox proportional hazards model.

CCI, Charlson Comorbidity Index; DCSI, Diabetes Complications Severity Index; DM, diabetes mellitus; P4P, pay for performance.

![The relative risk of stroke in patients with type 2 diabetes whether there were P4P participants or not participants (adjusted Cox proportional hazards model with controlling for other relevant variables). P4P, pay for performance.](bmjopen-2018-026626f01){#F1}

The other significant risk factors associated with incidence of stroke included gender, age, monthly salary, urbanisation of the residence area, CCI score, DCSI score, level of healthcare organisation, whether the main physician was an endocrinologist, the main physician's annual service volume, use of adult health check and the duration of DM. With regard to the gender factor, the risk of stroke in males was 1.42 times that of females. Concerning monthly salaries, and using low-income households as the reference group, the risk of stroke at increasingly higher income levels was between 0.99 and 0.68 times. For the severity of diabetic complications (DCSI), the higher the score, the higher the risk of stroke. When the main medical department was an endocrinologist unit, the risk of stroke was 0.91 times that of a non-endocrinologist main medical department. Regarding the adult health check, the risk of stroke was 0.92 times for those who took advantage of this option compared with those who did not.

The effect of the P4P programme on incidence risks of haemorrhagic stroke and ischaemic stroke and related factors in patients with type 2 diabetes {#s3-3}
---------------------------------------------------------------------------------------------------------------------------------------------------

A Cox proportional hazards model analysis found that the risk of haemorrhagic stroke in patients enrolled in the P4P programme was 0.87 times (95% CI 0.82 to 0.93) that of not enrolled patients ([table 3](#T3){ref-type="table"} and [figure 2](#F2){ref-type="fig"}). The incidence of haemorrhagic stroke in patients with diabetes enrolled in the P4P programme was 13% lower than that of the non-P4P group. In contrast, the Cox proportional hazards model determined that the risk of ischaemic stroke was similar between the P4P patients and those not included in this programme (HR=0.99, 95% CI 0.97 to 1.02, p=0.632) ([table 3](#T3){ref-type="table"} and [figure 2](#F2){ref-type="fig"}).

###### 

The effect of the P4P programme on incidence risks of haemorrhagic stroke and ischaemic stroke in patients with type 2 diabetes

                                         n         Haemorrhagic stroke   Ischaemic stroke                                                          
  -------------------------------------- --------- --------------------- ------------------ ------ ------ --------- -------- ------ -------------- ---------
  P4P participating status                                                                                                                         
   Non-P4P (ref)                         228 170   2158                                                             11 588                         
   P4P                                   228 170   1919                  0.87               0.82   0.93   \<0.001   11 908   0.99   0.97 to 1.02   0.632
  Gender                                                                                                                                           
   Female (ref)                          228 178   1698                                                             10 518                         
   Male                                  228 162   2379                  1.55               1.46   1.65   \<0.001   12 978   1.43   1.39 to 1.47   \<0.001
  Patient's age (years)                                                                                                                            
   45--54 (ref)                          138 867   953                                                              3907                           
   55--64                                159 357   1215                  1.18               1.08   1.28   \<0.001   6899     1.61   1.54 to 1.67   \<0.001
   65--74                                107 666   1188                  1.62               1.48   1.77   \<0.001   7996     2.63   2.52 to 2.73   \<0.001
   ≥75                                   50 450    721                   2.38               2.14   2.65   \<0.001   4694     3.80   3.63 to 3.98   \<0.001
  Monthly salary (US\$)                                                                                                                            
   ≤557                                  23 823    245                                                              1240                           
   557--735                              202 640   2096                  0.93               0.82   1.07   0.321     12 259   1.01   0.95 to 1.07   0.863
   735--929                              107 110   916                   0.81               0.70   0.93   0.003     5521     0.91   0.86 to 0.97   0.003
   929--1171                             40 062    263                   0.79               0.66   0.94   0.008     1409     0.84   0.78 to 0.90   \<0.001
   1171--1477                            41 864    276                   0.70               0.59   0.83   \<0.001   1597     0.80   0.75 to 0.87   \<0.001
   ≥1477                                 40 841    281                   0.67               0.56   0.79   \<0.001   1470     0.69   0.64 to 0.74   \<0.001
  Urbanisation of residence area                                                                                                                   
   Level 1 (ref)                         124 281   1005                                                             5204                           
   Level 2                               142 072   1184                  1.00               0.91   1.08   0.903     6765     1.10   1.06 to 1.14   \<0.001
   Level 3                               68 929    604                   1.00               0.90   1.10   0.920     3754     1.18   1.13 to 1.23   \<0.001
   Level 4                               70 311    725                   1.10               0.99   1.21   0.065     4396     1.25   1.20 to 1.30   \<0.001
   Level 5                               11 461    127                   1.08               0.90   1.31   0.410     739      1.16   1.08 to 1.26   \<0.001
   Level 6                               20 927    267                   1.31               1.14   1.50   \<0.001   1488     1.35   1.27 to 1.43   \<0.001
   Level 7                               18 359    165                   0.93               0.78   1.10   0.386     1150     1.21   1.13 to 1.29   \<0.001
  CCI score                                                                                                                                        
   0 (ref)                               288 669   2248                                                             13 386                         
   1                                     105 514   1053                  1.13               1.05   1.21   0.002     6050     1.01   0.98 to 1.04   0.476
   ≥2                                    62 157    776                   1.30               1.19   1.42   \<0.001   4060     1.02   0.98 to 1.06   0.282
  DCSI score                                                                                                                                       
   0 (ref)                               361 809   3004                                                             17 077                         
   1                                     59 900    571                   1.03               0.94   1.13   0.500     3579     1.10   1.06 to 1.14   \<0.001
   ≥2                                    34 631    502                   1.41               1.28   1.56   \<0.001   2840     1.39   1.34 to 1.45   \<0.001
  Level of the healthcare organisation                                                                                                             
   Medical centre                        81 845    607                   0.92               0.83   1.02   0.120     3518     0.89   0.85 to 0.92   \<0.001
   Regional                              153 179   1408                  1.12               1.03   1.21   0.008     7790     1.02   0.99 to 1.06   0.187
   District                              92 136    971                   1.16               1.06   1.26   0.001     5392     1.03   0.99 to 1.07   0.099
   Clinic (ref)                          129 180   1091                                                             6796                           
  Ownership of organisation                                                                                                                        
   Public (ref)                          106 906   937                                                              5426                           
   Non-public                            349 434   3140                  1.10               1.02   1.18   0.016     18 070   1.12   1.09 to 1.16   \<0.001
  Main physician is an endocrinologist                                                                                                             
   No (ref)                              379 138   3534                                                             20 366                         
   Yes                                   77 202    543                   0.87               0.79   0.95   0.003     3130     0.91   0.88 to 0.95   \<0.001
  Physician's annual service volume                                                                                                                
   Low (ref)                             6732      69                                                               362                            
   Medium                                49 061    498                   1.06               0.82   1.37   0.651     2705     1.13   1.01 to 1.26   0.035
   High                                  400 547   3510                  0.98               0.77   1.25   0.854     20 429   1.07   0.96 to 1.18   0.245
  Use of adult health check                                                                                                                        
   No (ref)                              200 805   1664                                                             8481                           
   Yes                                   255 535   2413                  0.84               0.78   0.90   \<0.001   15 015   0.92   0.89 to 0.95   \<0.001
  Duration of DM (years)                                                                                                                           
   \<3 (ref)                             252 506   2118                                                             11 342                         
   3--6                                  118 168   1238                  1.10               1.02   1.18   0.013     7621     1.21   1.17 to 1.24   \<0.001
   6--9                                  61 121    597                   1.19               1.09   1.31   \<0.001   3605     1.27   1.22 to 1.32   \<0.001
   ≥9                                    24 545    124                   0.89               0.74   1.07   0.221     928      1.19   1.11 to 1.28   \<0.001

\*Cox proportional hazards model.

CCI, Charlson Comorbidity Index; DCSI, Diabetes Complications Severity Index; DM, diabetes mellitus; P4P, pay for performance.

![The relative risks of haemorrhagic stroke or ischaemic stroke in patients with type 2 diabetes whether there were P4P participants or not participants (adjusted Cox proportional hazards model with controlling for other relevant variables). P4P, pay for performance.](bmjopen-2018-026626f02){#F2}

With regard to personal characteristics, both males and older patients had a higher risk of haemorrhagic and ischaemic stroke ([table 3](#T3){ref-type="table"}). As for the urbanisation of residence areas, with level 1 as the reference group, the risk of ischaemic stroke was higher at greater levels of urbanisation, but the risk of haemorrhagic stroke was not significantly influenced by this variable. Patients with a higher CCI score had a greater risk of haemorrhagic stroke rather than ischaemic stroke. Also, when patients had a higher DCSI score, the risk of ischaemic stroke was higher. The risks of both haemorrhagic and ischaemic stroke for patients who used an adult health check were lower compared with those who did not.

Stratified analysis of the risk of stroke in patients with type 2 diabetes by P4P programme {#s3-4}
-------------------------------------------------------------------------------------------

After we examined the interaction relationship between P4P enrolment status and related variables regarding the risks of stroke, this study found that only gender had a significant interaction relationship (p\<0.001), and all of our other numerous explanatory variables did not (p\>0.05). This study further conducted a stratified analysis for gender to compare the effect of P4P enrolment status on risk of stroke in both males and females, respectively. This effort showed that the reduced risk of stroke in males with diabetes enrolled in the P4P programme was greater than that of their female counterparts ([table 4](#T4){ref-type="table"}).

###### 

Stratification analysis: the effect of P4P programme on risk of stroke in different gender patients with type 2 diabetes

            Stroke (%)   Adjusted model                         
  --------- ------------ ---------------- ------ -------------- ---------
  Gender                                                        
   Female   5.87         5.58             1.02   0.98 to 1.06   0.285
   Male     6.95         7.21             0.93   0.90 to 0.97   \<0.001

\*Cox proportional hazards model.

P4P, pay for performance.

In addition, after we further analysed the average number of primary care visits per year by arm, we found that these values were 12.82 and 7.76 times for the P4P group and non-P4P group, respectively.

Discussion {#s4}
==========

The results of our Cox proportional hazards model showed a lower risk of stroke for patients with diabetes enrolled in the P4P programme (HR=0.97). The reason may be that the programme's clinical guidelines require physicians, nurses, pharmacists, nutritionists and case managers to form a team to co-care patients with diabetes.[@R10] Such a team approach to disease management might enhance the quality of care, thereby reducing the stroke risk in patients with diabetes.

Previous studies revealed that patients with diabetes enrolled in P4P programmes were more likely to receive all clinically specified tests (including HbA1c, blood pressure and LDL cholesterol),[@R24] and have lower hospitalisation expenses than those for non-participants.[@R13] The number of visits to diabetes clinics was much higher in patients with diabetes enrolled in P4P programmes, indeed 2.01 times more than that for the not enrolled patients.[@R13] Compared with those having low-continuity care scores, patients with higher scores on this metric were more likely to have better medication compliance.[@R10] The link between continuity of care and healthcare outcomes is partly due to better drug compliance in patients with type 2 diabetes.[@R10] This study found that the average number of annual primary care visits was higher in the P4P group than that in the non-P4P group (12.82 and 7.76 times, respectively). This result was similar to the existing literature.[@R13]

In 2006, Taiwan's NHI Administration hoped to, through quality incentives, encourage physicians to devote more attention to providing excellent medical care. One of the positive indicators is the patient's completed follow-up rate (based on a regular annual assessment to ensure continuous care). A previous study revealed that those who participated in P4P programmes had a 4.27-fold increase in continuous care compared with non-participants.[@R25] Furthermore, Chen *et al* found that P4P programme participants significantly improved their survival without increasing medical expenses when compared with non-participants.[@R12]

The cardiovascular complications of diabetes may cause myocardial infarction and stroke, with approximately 50% of deaths of patients with diabetes attributed to CVD.[@R2] An earlier study showed better HbA1c results and glycaemic control could be achieved by participating in a P4P diabetes programme.[@R26] Another investigation revealed that the enrolment of patients with type 2 diabetes in a P4P programme had a positive effect on HbA1c and glycaemic control; produced a decline in HbA1c within 6 months; and reduced the risk of stroke, myocardial infarction and death.[@R27] Moreover, it has been shown that a patient-centred, multidisciplinary care model could effectively reduce the incidence of cardiovascular complications (coronary heart disease, heart failure and stroke) in patients with diabetes (HR=0.652).[@R28] These earlier studies may help explain the lower risk of stroke observed in our study regarding patients who were enrolled in Taiwan's Diabetes P4P programme.

Our use of a Cox proportional hazards model revealed a lower risk of haemorrhagic stroke (HR=0.87) in patients who were enrolled in Taiwan's DM P4P programme, which includes blood pressure checks during the physical examination in every care visit in the P4P programme. High blood pressure increases the risk of stroke by four times,[@R29] and the effect of blood pressure on haemorrhagic stroke is more significant than that on ischaemic stroke.[@R6] Previous studies have revealed that chronic kidney disease is also a risk factor for haemorrhagic stroke, and the poorer the renal function, the higher the risk of this outcome.[@R31] A possible explanation is that chronic kidney disease affects platelet aggregation, causing a bleeding tendency. Studies of patients with haemorrhagic stroke have shown that those with chronic kidney disease are more likely to develop cerebrovascular bleeds and microbleeds.[@R32] Chen *et al* demonstrated increased survival in P4P programme participants compared with not enrolled patients, increased compliance with the use of hypoglycaemic agents and a reduced risk of cancer and chronic kidney disease.[@R12]

Our study revealed that patients with type 2 diabetes in low-income households had a higher risk of stroke than those with higher incomes, perhaps because poor people are less likely to seek medical treatment and are, consequently, less likely to receive diabetes-related tests. Thus, poverty increases the incidence of diabetes and the inequality of diabetic care.[@R33] Patients with low socioeconomic status are less involved in medical decisions, have less access to medical information and are less likely to communicate effectively with physicians.[@R34]

This study also found a lower risk of stroke in patients using an adult health check compared with those who did not. A previous study has demonstrated that patients with diabetes who actively use self-care can reduce the incidence of diabetic complications.[@R35] There is a statistically significant difference between the health-oriented beliefs of health check users and non-users.[@R35] Compared with non-users, health check users think their health is more valuable and more susceptible to disease.[@R36] A previous study showed that when people feel more social support, when people believe they have the ability to receive health checks, or when they have more health information, they participate more actively in health checks.[@R37] Previous studies have also shown that factors related to healthy behaviour could influence the use of the adult health check. For example, smokers, people who chew betel nut and those choosing a sedentary lifestyle had seldom elected to have an adult health check.[@R38] The Taiwan adult health check includes a physical examination, biochemical blood tests, renal function tests and health consultations, and this annual adult health check is free.[@R21]

Following a stratified analysis of the gender element, our study revealed that compared with men not in the P4P programme, men in the P4P programme had a significantly lower risk of stroke, whereas this was not true for females enrolled in a P4P programme. An earlier study reported that female patients have better medical compliance behaviour than males.[@R39] Therefore, when males with diabetes enrolled in the P4P programme, they may have significantly improved their medical compliance and thereby have lowered their risk of having a stroke.

Limitations {#s4-1}
-----------

Patients with diabetes who visited outpatient clinics less than three times or who were not hospitalised with a primary diagnosis or subdiagnosis of DM (ICD-9-CM 250, A code: A181) within 365 days were excluded from this study. This protocol might cause a reduced actual number of people with diabetes. However, this study still had a big number of study participants to enhance the study findings. Our study database did not include some other factors such as HbA1c, body mass index (BMI), blood pressure and compliance with medication. However, previous studies showed that patients with diabetes enrolled in P4P programmes were more likely to receive clinically specified tests (HbA1c, BMI, blood pressure, LDL cholesterol)[@R24] and had better medication compliance.[@R10] Therefore, these limitations may not affect the results of this study.

Behavioural changes regarding adult health checks and new comorbidity conditions that could not be followed were also limitations of this investigation. Finally, we performed PSM between the P4P and non-P4P groups to reduce selection bias which might not have eliminated all selection bias between two groups, but we further conducted multivariate model controlling for relevant variables which would enhance the unbiased results.

Conclusions {#s5}
===========

Our results indicate that the factors affecting the risk of stroke in patients with diabetes were P4P programme enrolment status, gender, age, monthly salary, degree of urbanisation, comorbidity (CCI), severity of complications (DCSI), characteristics of the primary healthcare organisation, characteristics of the primary physician, the use of an adult health check and the duration of DM.

Patients with type 2 diabetes enrolled in the P4P programme had a significantly lower risk of stroke (HR=0.97), especially haemorrhagic stroke (HR=0.87). However, there was no statistically significant difference in the risk of ischaemic stroke (HR=0.99). Male patients with diabetes enrolled in the P4P programme exhibited a more significant reduction in stroke risk.

Recommendation {#s5-1}
--------------

Our results could provide a reference for the quality of care and case management of diabetes. The P4P programme may be promoted to patients with type 2 diabetes, especially male patients, and also to their physicians.
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